A Long-term Study of PA21 in Hemodialysis Patients With Hyperphosphatemia
A Long-term Study of PA21 in Hemodialysis Patients With Hyperphosphatemia
The purpose of this study is to investigate the safety and efficacy for 52-week dosing in hemodialysis patients with hyperphosphatemia.
Inclusion Criteria:
Exclusion Criteria:
Multiple Locations, Japan